NDSN · Q4 2025 Earnings
CautiousNordson Corporation
Reported December 10, 2025
30-second summary
30-second take: Nordson closed FY2025 with Q4 revenue of $752M (+1% YoY) and non-GAAP EPS of $3.03, with Medical and Fluid Solutions +9.6% offsetting Industrial Precision Solutions -1.5% and Advanced Technology Solutions -3.6%. FY2026 guidance of $2.83–2.95B revenue (+1–6% YoY) and $10.80–11.50 EPS (+6–12%) confirms management's "trough is behind us" thesis but at a pace that barely improves on FY2025's +3.8%. EBITDA margin held at 34% and FCF conversion hit 128% — the operational story remains intact; the demand story is still waiting on a real inflection.
Headline numbers
EPS
Q4 FY2025
$3.03
Revenue
Q4 FY2025
$0.75B
+1.0% YoY
Gross margin
Q4 FY2025
56.3%
Operating margin
Q4 FY2025
28.5%
Key financials
Q4 FY2025| Metric | Q4 FY2025 | YoY | Q3 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $0.75B | +1.0% | $0.74B | +1.4% |
| EPS | $3.03 | — | $2.73 | +11.0% |
| Gross margin | 56.3% | — | 54.8% | +150bps |
| Operating margin | 28.5% | — | 25.3% | +320bps |
Guidance
Company reaffirms FY2025 performance and guides FY2026 revenue growth of 1–6% YoY and adjusted EPS growth of 6–12% YoY, signaling modest top-line recovery with margin expansion as end-market inflections begin.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Revenue | Q4 FY2025 | slightly below the midpoint of full year sales guidance | $752 million | in-line | Met |
| Adjusted EPS | Q4 FY2025 | slightly better than midpoint of full year guidance | $3.03 non-GAAP | above guidance | Beat |
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Revenue | FY2026 | $2,830 to $2,950 million | +1% to +6% YoY |
| Adjusted EPS | FY2026 | $10.80 to $11.50 | +6% to +12% YoY |
| Revenue | Q1 FY2026 | $630 to $670 million | — |
| Adjusted EPS | Q1 FY2026 | $2.25 to $2.45 | — |
Segment KPIs
Q4 FY2025| Segment | Q4 FY2025 | YoY |
|---|---|---|
| Industrial Precision Solutions | $0.362B | -1.5% |
| Medical and Fluid Solutions | $0.22B | +9.6% |
| Advanced Technology Solutions | $0.171B | -3.6% |
| Industrial Precision Solutions EBITDA Margin | 37.9% | — |
| Medical and Fluid Solutions EBITDA Margin | 39.8% | — |
| Advanced Technology Solutions EBITDA Margin | 25.1% | — |
Other KPIs
Q4 FY2025| Segment | Q4 FY2025 | YoY |
|---|---|---|
| Americas | $0.331B | +2.4% |
| Europe | $0.195B | +5.4% |
| Asia Pacific | $0.226B | -4.4% |
| EBITDA | $256 million | — |
| EBITDA Margin | 34.0% | — |
| Operating Margin | 28.5% | — |
| Free Cash Flow Conversion | 128% | — |
| Backlog | ~$600 million | — |
Management tone
Narrative arc: Q2 ATS reacceleration + IPS restructuring → Q3 multi-segment trough call → Q4 "headwinds behind us" optimism despite organic give-back.
Three quarters ago IPS was being actively restructured for >$15M of 2026 savings while management waited for demand to return. Two quarters ago they called the trough explicitly ("we believe this business has hit its trough"). This quarter, with IPS still printing -1.5% YoY, management escalated to declaring "key market headwinds behind us" and pointing to polymer processing and industrial coding as "no longer a drag." The verbal escalation is running ahead of the segment numbers — IPS hasn't actually inflected, it has merely stopped falling further. The +1–6% FY26 sales guide quietly concedes this; management is optimistic about direction but conservative about magnitude.
ATS framing completed a full cycle from "lumpy" caveats to confirmation of that lumpiness. Last quarter management preemptively warned that "demand in this business inherently is lumpy" and flagged Q4 comp risk. Q4 delivered -3.6% YoY, validating the caveat. The forward pitch is now anchored on semiconductor exposure (50% of ATS revenue) tied to AI/cloud — the Moran/Hammond exchange confirmed Q1 ATS growth will benefit from favorable YoY comps after a soft Q1 FY2025 start. The new "Q1 strong" framing therefore depends partly on a base effect, not pure demand strength.
Medical destocking moved from "severity reducing" (Q2) to "now fully behind us" (Q4), with the interventional business explicitly back to "mid-single digit organic growth." This is the cleanest cross-quarter resolution in the file. The CDMO divestiture is expected to add ~100bps to medical segment margins in FY26 per the DA Davidson exchange, though management cautioned the Q4 40%+ print is not the new normal.
M&A tone shifted from "Atrion accreted a year ahead of plan" energy in Q3 to a flat "no actionable deals met both strategic and financial criteria in 2025" admission in Q4. The pipeline is described as healthy but management explicitly named ~$250 buybacks as "actionable" given a recent authorization increase. Read this as a quiet signal that capital return — not acquisitions — is the most likely near-term deployment lever.
The overall posture is unusually optimistic for a company that just posted organic sales declines in two of three segments. As the tone extraction put it: management is "front-running visibility into demand recovery rather than waiting for confirmed results."
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Mike Halloran · Baird
Is strength in ETS semiconductor segment broadening beyond AI/data center to traditional electronics (auto, general electronics)? What are the right margin levels to model for 2026, particularly given strong medical segment performance this quarter?
Semiconductor strength remains concentrated in AI/cloud computing applications. Automotive stabilizing and general electronics growing slower than semiconductors. Revenue split: 50% semiconductor, 15% automotive, rest electronics. Medical segment margins at 40%+ this quarter are not sustainable; upper 30s is the right level, driven by portfolio changes and operational tailwinds. ETS and IPS margins represent appropriate jump-off points. Divestiture expected to improve segment margins by ~100 basis points.
Mitch Moran · KeyBank
Within IPS, polymer processing weakness is masking stable growth elsewhere. What are expectations for polymer processing vs. the rest of the business in 2026? What is the order intake and backlog trajectory?
Polymer processing has bottomed out in order entry and backlog. Expectations are for improvement from the trough, not further deterioration. The weakness is not expected to continue dragging on IPS. For ATS Q1, healthy growth implied is driven by good underlying stable demand in semiconductors, electronics, automotive, and general electronics, plus favorable year-over-year comps from slow Q1 start last year. Stronger backlog position entering 2026 vs. prior year start.
Matt Somerville · DA Davidson
Why is X-ray inspection growth decoupled from broader AI/cloud-driven semiconductor growth? Are new product launches and technology transitions driving upside? Also, what is the M&A strategy and capital allocation philosophy at current valuation?
X-ray has solid automotive exposure, which differs from broader semiconductor trends. Company is excited about new product launches. X-ray benefits from advanced chip architectures with both logic and memory, where acoustic is used for memory and X-ray for logic. Technology transition underway in testing; new technologies currently being tested but likely impact in 2027, not 2026. X-ray in good position to contribute to ATS growth in 2026. M&A strategy remains focused on highly differentiated, strategically and financially disciplined acquisitions. Pipeline is healthy but 2025 saw no actionable deals meeting both strategic and financial criteria. Capital allocation is balanced between share buybacks and acquisitions. Stock remains actionable for buybacks at $250 range with recent authorization increase providing near-term coverage.
Andrew Buscalia · BNP
If tougher markets have troughed, why does low-end guidance assume minimal growth? What risks exist that warrant a conservative low-end case? How does management perceive IPS sensitivity to industrial production and outlook for industrial factors recovery in 2026?
Guidance range reflects planning for both upside and downside scenarios. Q1 strong, first quarter implied in guidance. Downside case contemplates 'something happens' but management sees no current indicators of downsides. As the year plays out, guidance will be updated. For IPS in 2025, the segment was weighed down by polymer processing weakness and automotive decline, which masked core IPS progress. Precision Ag grew double-digit in 2025 and is expected to continue strong, with good order entry and backlog visibility. Automotive has troughed and stabilized; any recovery is upside. IPS business expected to achieve GDP-plus growth in 2026 with polymer processing and automotive recovery providing upside. Aftermarket parts (55-56% of IPS revenue) expected to see stable demand.
Brad Hewitt · Wolf Research
Can you quantify sequential backlog trends and provide business-level detail? Is normal seasonality expected in 2026 for both revenue/EBITDA and organic growth split between H1 and H2?
Backlog up 5% year-over-year but down sequentially, which is normal given Q1 is seasonally the lowest quarter due to holidays and year-end timing. Expecting normal seasonality in 2026, with Q1 being the lowest quarter and sequential improvement throughout the year. Chinese New Year is in Q2 this year with nominal impact. Organic growth expected to follow similar patterns in H1 vs. H2.
Answers to last quarter's watch list
What to watch into next quarter
Whether Q1 ATS growth materializes given management's "Q1 strong" framing — they explicitly attributed it partly to favorable YoY comps off a soft Q1 FY2025 base, so the underlying demand signal is muddier than headline growth will suggest
IPS Q1 organic growth — a third consecutive quarter at or below zero would force management to walk back the "headwinds behind us" framing
Medical segment EBITDA margin post-CDMO close — does the segment settle into the "upper 30s" range management called out, and does the ~100bps divestiture accretion show up cleanly in Q1
FY26 revenue guide updates — if Q1 prints strong and management does not raise the FY range, the +1–6% guide is signaling caution about H2 that wasn't visible in the prepared remarks tone
Backlog quality — another sequential decline in Q1 (even if seasonally explained) combined with the YoY+5% moving toward zero would invalidate the "stronger entering FY26" thesis
Buyback pace at the stated ~$250 actionable level — management explicitly framed the stock as actionable; meaningful Q1 repurchase activity would confirm capital allocation has shifted away from M&A
Sources
- Nordson Corporation Q4 FY2025 press release — https://www.sec.gov/Archives/edgar/data/72331/000007233125000138/ndsn-20251213xex991.htm
- Nordson Corporation Q4 FY2025 earnings call transcript
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.